Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Previous studies have reported controversial results regarding the risk of restenosis with polymorphisms of endothelial nitric oxide synthase (eNOS), matrix metalloproteinase 3 (MMP-3), angiotensinogen (AGT), and angiotensin II type 1 receptor (AT1R) after percutaneous coronary intervention (PCI). This study aimed to summarize the association between these polymorphisms and risk of restenosis after PCI.
Methods: We searched the electronic databases of PubMed, Embase, Cochrane's Library, and ClinicalTrials.gov for studies on the association of eNOS, MMP-3, AGT, and AT1R polymorphisms with restenosis.
Findings: A total of 17 studies (7781 patients) were analyzed, including 5 studies on eNOS G298A (n = 912), 5 studies on MMP3 5A/6A (n = 4519), 6 studies on AGT M235T (n = 1801), and 7 studies on AT1R A1166C (n = 2477). For the G298A variant of the eNOS gene, the allele odds ratio (OR) was 1.685 (95% CI, 1.269-2.338; P < 0.001), the heterozygote OR was 2.144 (95% CI, 1.490-3.085; P < 0.001), the dominant OR was 2.078 (95% CI, 1.462-2.954; P < 0.001), and the overdominant OR was 0.496 (95% CI, 0.348-0.706; P < 0.001). For the 5A/6A variant of the MMP3 gene, the heterozygote OR was 0.839 (95% CI, 0.722-0.975; P = 0.022), the dominant OR was 0.846 (95% CI, 0.733-0.976; P = 0.022), and the overdominant OR was 1.141 (95% CI, 1.001-1.301; P = 0.049). For the M235T variant of the AGT gene, the heterozygote OR was 1.594 (95% CI, 1.179-2.155; P = 0.002), the dominant OR was 1.437 (95% CI, 1.077-1.918; P = 0.014), and the overdominant OR was 0.694 (95% CI, 0.555-0.869; P = 0.001). Positive results were observed in the AT1R gene A1166C polymorphism under 3 models (homozygote OR = 2.009; 95% CI, 1.433-2.816; P < 0.001; recessive OR 1.874; 95% CI, 1.353-2.595; P < 0.001; and dominant OR = 1.350; 95% CI, 1.105-1.649; P = 0.003).
Implications: The G298A variant of eNOS, the 5A/6A variant of MMP3, the M235T variant of AGT, and the A1166C variant of A1TR may increase the risk of restenosis after PCI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinthera.2020.01.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aim To compare the results of primary percutaneous coronary intervention (PCI) for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) in patients who recently recovered from COVID-19 with those not previously infected with SARS-CoV-2; to establish prognostic criteria for PCI complications, including stent thrombosis and restenosis (ST and SR) and progression of ischemic heart disease, and to determine ways to prevent them.Material and methods In 2021, middle-aged patients admitted to the Baku Central Clinical Hospital with a diagnosis of acute coronary syndrome who underwent urgent myocardial revascularization using percutaneous balloon angioplasty of the occluded coronary artery (CA) with implantation of a second-generation intracoronary drug-eluting stent were divided into two observation groups: the main group of 123 patients who had COVID-19 in the previous 6 months, and the control group of 112 patients who were not previously infected with SARS-CoV-2. The immediate results of PCI were assessed according to the TIMI scale; complications were assessed both clinically, by the incidence of severe complications (major adverse cardiovascular events, MACE), and angiographically, by the incidence of early and late ST and SR, and de novo stenosis that developed during the two-year observation period.
View Article and Find Full Text PDFDrug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial.
Circulation
September 2025
Division of Cardiology, Columbia University Irving Medical Center, New York, NY (S.A.P.).
Background: Limited treatment options exist for infrapopliteal disease in patients with chronic limb-threatening ischemia (CLTI), a condition associated with a high risk of limb loss. Interventional management of diseased infrapopliteal vessels with percutaneous transluminal angioplasty (PTA) is associated with high rates of restenosis and reintervention. In the LIFE-BTK trial, the drug-eluting resorbable scaffold (DRS) demonstrated superior 12-month efficacy compared with PTA in a selected CLTI population with predominantly noncomplex, mildly to moderately calcified lesions.
View Article and Find Full Text PDF"Cut and Cover": A Case Series of Dual Modality Treatment With Stricturetomy and Stenting for Inflammatory Bowel Disease-Related Strictures.
Cureus
August 2025
Gastroenterology and Hepatology Division of the Department of Internal Medicine, University of Michigan, Ann Arbor, USA.
Strictures are common in inflammatory bowel disease (IBD) and are managed medically and endoscopically, if feasible, due to the risk of surgical complications. While endoscopic balloon dilation (EBD) is often successful, the need for repeat dilation and subsequent surgery is common. Endoscopic stricturotomy (ESt) has gained popularity but has been limited by frequent post-procedural bleeding.
View Article and Find Full Text PDFOne-year outcomes of polymer-free Sirolimus-eluting stents in complex femoropopliteal stenosis: a single center real-world registry.
J Cardiovasc Surg (Torino)
September 2025
Catheterization Laboratory, Montevergine Clinic, Mercogliano, Avellino, Italy -
Background: Lower extremity arterial disease is a prevalent vascular condition leading to ischemic symptoms and increased risk of cardiovascular events. Drug-eluting stents have improved outcomes by reducing restenosis, with sirolimus emerging as a promising alternative to paclitaxel due to its safer profile. This study evaluates the efficacy and safety of novel polymer-free Amphilimus formulation (Sirolimus + fatty acid) eluting self-expanding stent in the treatment of femoropopliteal disease in a real-world population.
View Article and Find Full Text PDFRisk factors for coronary in-stent restenosis in Moroccan patients: a retrospective case-control study.
Cell Mol Biol (Noisy-le-grand)
September 2025
Medical School, Laboratory of Genetics and Molecular Pathology, University Hassan II, Casablanca, Morocco.
In-stent restenosis remains a significant challenge in interventional cardiology despite technological advancements. This retrospective case-control study conducted at the University Hospital Center Ibn Rochd in Casablanca (2020-2023) examined risk factors associated with coronary in-stent restenosis in 68 patients equally distributed between restenosis and no-restenosis groups. Diabetes emerged as a powerful predictor of restenosis (RR=4.
View Article and Find Full Text PDF